A Sponsor's Review of the Impairment Risk of the Listing Applicant's Intangible Assets

The HKEX Listing Committee’s decision in Re [Applicant] (HKEX Listing Decision LD143-2025, December 2025), which rejected a listing application due to the sponsor’s failure to adequately substantiate the recoverable amount of goodwill and acquired in-process R&D (IPR&D) from a pre-IPO acquisition, has reset the baseline for sponsor diligence on intangible assets. This decision, alongside the SFC’s Thematic Inspection of Sponsor Work on Impairment Assessments (SFC, October 2025) which found that 62% of reviewed IPO files contained “materially inadequate” impairment testing documentation, creates a combined regulatory signal: the era of accepting management-prepared, cash-flow-based models without independent challenge is over. For a sponsor holding a Type 6 (advising on corporate finance) or Type 6A (sponsor) licence, the impairment risk of an applicant’s intangible assets is no longer a footnote in the accountants’ report but a core due diligence workstream that directly determines listing eligibility under HKEX Listing Rule 9.03(1) and the sponsor’s own fitness and properness under the SFC Code of Conduct (Paragraph 17). This article dissects the mechanics of a sponsor’s review of intangible asset impairment, moving from the regulatory framework through to the practical execution of independent testing, and concludes with the documentation standards now expected by the Listing Division.

The Regulatory Floor: Listing Rules, SFC Codes, and Accounting Standards

HKEX Listing Rule 9.03(1) and the Sufficiency of Operations Requirement

The threshold for listing is not merely that an applicant is profitable, but that it has a “sufficient level of operations and assets of sufficient value” to warrant a listing. HKEX Listing Rule 9.03(1) requires the Exchange to be satisfied that the applicant’s business is “sustainable and viable” for at least the next 12 months. When an applicant’s balance sheet is dominated by intangible assets—often 70-80% of total assets for technology or biotech firms—the impairment risk of those assets becomes the single largest determinant of that sustainability.

The Listing Committee’s LD143-2025 decision explicitly stated that the sponsor’s failure to “independently verify the key assumptions used in the impairment model, particularly the revenue growth rate and the discount rate” rendered the applicant’s financial projections unreliable for the purposes of Rule 9.03(1). The decision cited the sponsor’s reliance on management-prepared cash flow forecasts without conducting its own sensitivity analysis on the carrying value of goodwill—a direct breach of the sponsor’s duty to exercise “reasonable care and diligence” under the SFC Code of Conduct (Paragraph 17.3).

SFC Code of Conduct Paragraph 17: The Sponsor’s Duty on Financial Projections

Paragraph 17 of the SFC Code of Conduct for Persons Licensed by or Registered with the SFC imposes a specific duty on sponsors to “take reasonable steps to satisfy themselves that the financial projections and other forward-looking statements in the listing document are not misleading and have a reasonable basis.” This duty extends directly to impairment testing. The SFC’s 2025 thematic inspection found that in 38% of files reviewed, sponsors accepted management’s discount rate (WACC) without any independent calculation or cross-reference to comparable companies’ cost of capital. In 22% of files, the sponsor did not even request the external valuer’s report on the intangible asset’s fair value.

The SFC’s enforcement action in SFC v. [Sponsor Firm] (SFC, March 2025) resulted in a HKD 12 million fine and a 2-year suspension of the sponsor’s licence for precisely this failure. The SFC found that the sponsor had “rubber-stamped” a management-prepared impairment model that used a terminal growth rate of 3.5% for a technology company operating in a mature, low-growth market—a rate that the SFC’s expert described as “unsupportable by any market data.”

HKAS 36 and HKFRS 3: The Accounting Backbone

While the sponsor is not the auditor, the sponsor must understand the accounting framework to challenge the auditor’s conclusions. HKAS 36 Impairment of Assets requires an entity to test goodwill and indefinite-life intangible assets for impairment at least annually, or more frequently if impairment indicators exist. The impairment test under HKAS 36 compares the carrying amount of a cash-generating unit (CGU) to its recoverable amount, defined as the higher of fair value less costs of disposal (FVLCD) and value in use (VIU).

The sponsor’s review must focus on the key assumptions in the VIU calculation: (i) the projected cash flows, (ii) the growth rate, and (iii) the discount rate. Under HKFRS 3 Business Combinations, goodwill acquired in a business combination must be allocated to the CGU that is expected to benefit from the combination. A common failure observed by the SFC is the misallocation of goodwill to a single CGU when the acquisition actually benefits multiple CGUs, thereby understating the impairment risk of the combined entity.

The Sponsor’s Independent Workstream: From Model Challenge to Sensitivity Analysis

Step 1: Deconstructing the Management Cash Flow Model

The sponsor’s first substantive task is to obtain and independently review the management-prepared cash flow model used for the impairment test. This model must be the same model used by the applicant’s management for its own internal impairment assessment under HKAS 36. The sponsor should request the model in its native format (e.g., Excel with formulas visible) and not merely a PDF summary.

The critical review points for the sponsor’s team are:

• Revenue build-up: Does the model derive revenue from unit volume and selling price, or is it a top-down market share assumption? The SFC’s 2025 inspection found that 45% of models used a top-down approach that could not be reconciled to the applicant’s actual sales data. The sponsor must request and review the applicant’s historical sales data for at least 36 months to validate the model’s base year assumptions.

• Cost structure: Are the operating cost projections consistent with the applicant’s historical cost ratios? A common red flag is a projected improvement in gross margin from 45% to 60% within two years without a clear, documented plan for cost reduction or product mix shift. The sponsor should compare the projected margins to industry benchmarks from comparable listed companies (e.g., Bloomberg peer analysis) and require management to provide a written explanation for any material deviation.

• Capital expenditure: Does the model assume a level of capex that is sufficient to maintain the asset base? An impairment model that projects high cash flows but minimal capex is inherently unreliable, as it assumes the intangible asset can generate returns without ongoing investment. The sponsor should verify that the capex assumption is at least equal to the amortisation of the intangible asset over the projection period.

Step 2: Independent Calculation of the Discount Rate (WACC)

The discount rate is the single most sensitive assumption in any impairment model. A 100 bps change in the WACC can change the recoverable amount by 15-25% for a typical technology company. The sponsor cannot accept management’s WACC without independent calculation.

The sponsor should calculate the WACC using the following methodology:

• Cost of equity (Ke): Use the Capital Asset Pricing Model (CAPM) with a risk-free rate based on the 10-year HKD or USD government bond yield (as applicable to the applicant’s functional currency). The equity risk premium should be derived from a recognised source such as Damodaran, KPMG, or Duff & Phelps. The beta should be based on a peer group of at least 5-10 comparable listed companies, un-levered and re-levered to the applicant’s target capital structure.

• Cost of debt (Kd): Use the applicant’s actual borrowing rate, or if the applicant has no debt, use a synthetic rating based on the applicant’s interest coverage ratio and the corresponding yield for that rating.

• Capital structure: Use the applicant’s target capital structure, not its current structure. If the applicant is entirely equity-funded, the WACC will equal the cost of equity, which is typically higher than a blended rate.

The sponsor must document the source of each input and the calculation methodology. The SFC’s 2025 inspection specifically flagged the use of an “unsupported” beta of 0.8 for a high-growth technology company, noting that the comparable peer group had a median beta of 1.3. The sponsor’s failure to reconcile this discrepancy was cited as a contributing factor to the enforcement action.

Step 3: Sensitivity Analysis and Reasonable Worst-Case Scenarios

HKAS 36 does not mandate sensitivity analysis, but the SFC’s Code of Conduct (Paragraph 17.3) requires the sponsor to assess whether the financial projections are “not misleading.” A single-point estimate of recoverable amount that is only 5% above the carrying value is inherently misleading if a 100 bps increase in the discount rate would impair the asset.

The sponsor must prepare a sensitivity table showing the recoverable amount under at least three scenarios: (i) base case (management’s assumptions), (ii) a 100 bps increase in WACC, and (iii) a 10% reduction in projected revenue growth. If any of these scenarios results in the recoverable amount falling below the carrying amount, the sponsor must require management to either recognise an impairment charge or provide a detailed justification for why the base case assumptions are more likely than the sensitivity scenario.

The Listing Committee in LD143-2025 specifically criticised the sponsor for not presenting a “reasonable worst-case” scenario. The decision noted that the applicant’s revenue in the two quarters following the submission date was 18% below management’s forecast, which would have triggered an impairment under the sponsor’s own sensitivity analysis—had one been performed.

Documentation Standards: What the Listing Division and SFC Expect

The Sponsor’s Due Diligence Memorandum

The sponsor must produce a dedicated section in the due diligence memorandum (DDM) on intangible asset impairment. This section should include:

• A summary of the impairment model’s key assumptions and the sponsor’s independent verification of each assumption.
• The sponsor’s independent WACC calculation, with all source inputs documented.
• The sensitivity analysis table, with a clear statement of the headroom (the excess of recoverable amount over carrying amount) under each scenario.
• A conclusion on whether the impairment risk is “material” (defined by the SFC as a headroom of less than 10% of the carrying amount) and, if so, the sponsor’s recommendation to the applicant.

The DDM must be signed off by the sponsor’s principal and the responsible officer (RO) with Type 6A registration. The SFC’s 2025 inspection found that 30% of DDM sections on impairment were unsigned or lacked the RO’s personal review—a deficiency that the SFC considers a breach of the sponsor’s management and supervision obligations under the Code of Conduct (Paragraph 17.6).

The External Valuer’s Report

If the applicant engages an external valuer to perform the impairment test (as is common for IPR&D or brand valuations), the sponsor must not treat the valuer’s report as a substitute for its own analysis. The sponsor must:

• Review the valuer’s engagement letter to confirm the valuer is independent and qualified (e.g., RICS, IVSC, or HKIS accredited).
• Challenge the valuer’s assumptions, particularly the discount rate and the terminal value, using the same methodology described above.
• Obtain the valuer’s underlying model and reconcile it to the management-prepared model.

The SFC’s enforcement action in SFC v. [Sponsor Firm] specifically noted that the sponsor had “delegated” its due diligence to the external valuer without independent review. The SFC’s view is clear: the sponsor, not the valuer, bears the ultimate responsibility for the accuracy of the impairment assessment in the listing document.

The Prospectus Disclosure

Under HKEX Listing Rule 11.07, the prospectus must include a discussion of the applicant’s “financial condition and prospects,” which includes the risk of intangible asset impairment. The sponsor must ensure that the risk factor section includes a specific disclosure on impairment risk, including:

• The carrying amount of the intangible assets as a percentage of total assets.
• The key assumptions used in the impairment test.
• The headroom under the base case and the sensitivity scenarios.
• A statement that there can be no assurance that an impairment charge will not be required in the future.

The Listing Committee in LD143-2025 found that the prospectus’s risk factor section merely stated that “impairment may occur” without quantifying the headroom or the sensitivity—a disclosure the Committee described as “generic and insufficient to inform investors of the specific risk.”

Practical Takeaways for the Sponsor’s Compliance Desk

1. The WACC is the single most contested assumption: The sponsor must prepare an independent WACC calculation using a documented peer group and a recognised risk premium source, and this calculation must be included in the DDM with the RO’s personal sign-off.

2. Sensitivity analysis is now mandatory in practice: Even though HKAS 36 does not require it, the SFC’s 2025 inspection and the LD143-2025 decision make clear that a sponsor must present at least a 100 bps WACC sensitivity and a 10% revenue sensitivity scenario in the DDM and, if headroom is below 10%, in the prospectus risk factors.

3. The external valuer is not a safe harbour: The sponsor must independently challenge the valuer’s assumptions and document that challenge in the DDM. Relying solely on the valuer’s report is a breach of Paragraph 17 of the SFC Code of Conduct.

4. Historical data must support the model’s base year: The sponsor must obtain and review at least 36 months of the applicant’s actual financial data to validate the revenue build-up and cost structure assumptions in the impairment model. A top-down market share approach without bottom-up unit-volume support is a regulatory red flag.

5. Documentation must be contemporaneous and signed: The impairment section of the DDM must be completed before the listing application is submitted, signed by the RO, and include the sponsor’s independent WACC calculation and sensitivity analysis. Post-hoc documentation is not acceptable to the SFC or the Listing Division.